UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038673
Receipt number R000044079
Scientific Title Down syndrome's estimate Glomerular Filtration Rate formula study
Date of disclosure of the study information 2019/12/01
Last modified on 2020/05/26 13:47:46

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Children with Down syndrome's renal function formula study

Acronym

DeGFR study

Scientific Title

Down syndrome's estimate Glomerular Filtration Rate formula study

Scientific Title:Acronym

DeGFR study

Region

Japan


Condition

Condition

Down syndrome
eGFR<90 ml/min/1.73m2

Classification by specialty

Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Since the renal function is evaluated by the formula from the standard values of healthy children, it is not valid for children with Down syndrome with different average height and muscle mass. Therefore, aiming to create a disease-specific renal function evaluation formula.

Basic objectives2

Others

Basic objectives -Others

Construction of eGFR estimation formula using coefficients specific to children with Down syndrome of obtained from linear regression of inulin clearance and [(reference serum Cr/patient's serum Cr)*100]

Trial characteristics_1


Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

inulin clearance
Blood test: creatinine, inulin
Before test start, 30 minutes after start, 90 minutes later

Urinalysis: creatinine, inulin
Before test start, at start, after 60 minutes, after 120 minutes

Key secondary outcomes

Gender, age, height, complications
Blood test: Cystatin C, B2MG
Urinalysis: B2MG
separate quantitative renal function: 99mTc-DMSA
Congenital anomalies of the kidney and urinary tract: Abdominal ultrasonography
Comparison with eGFR obtained from Uemura's formula


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment

No need to know


Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Medicine

Interventions/Control_1

All children are hospitalized for 2 days and examined. The same person is not measured repeatedly only once for each subject.
The amount of drugs and fluid replacement is calculated based on the weight at the time of hospitalization.
Abdominal ultrasonography and separate quantitative renal function (99mTc-DMSA) on day 1 and inulin clearance measurement on day 2.
The first day will be fasted after dinner, and the second day will not be allowed to drink from morning until the end.
Insert a bladder indwelling catheter for urinalysis during the study,
First, they receive an intravenous Ringer's solution load of 20 ml/kg body weight for 30 min to obtain good diuresis, following by a load of 5 ml/kg/h until testing completion. From 30 min after water loading, inulin give intravenously in a priming dose of 40 mg/kg body weight for 30 min calculated to achieve an extracellular fluid (ECF) level of 20 mg/dl. After the priming dose, administere inulin at a rate calculate to maintain a constant level in the blood. For this purpose, the rate of inulin infusion must equal that of loss in the urine. To calculate inulin loss, eGFR estimate from serum creatinine by the Uemura's formula. Therefore, the patients received an inulin load of 0.7 * eGFR ml/m2/h with calculation of body surface area by the Haycock method. We collect Urine samples in two periods of 1 h each, and blood samples twice from an indwelling cannula in the middle of urine collection, collect urine samples of all children by indwelling catheters.
After administration, confirm that there are no adverse events, and terminate the procedure.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

2 years-old <=

Age-upper limit

18 years-old >=

Gender

Male and Female

Key inclusion criteria

Meets all of the following
Down syndrome
2 to 18 years old
eGFR<90 ml/min/1.73m2: Uemura's formula

Key exclusion criteria

Any one of the following
congenital anomalies of the kidney and urinary tract
chronic glomerulonephritis
Respiratory or heart failure requiring oxygen administration
Under treatment for gastrointestinal symptoms and infectious diseases, inflammatory diseases
Women who are pregnant or may be pregnant
neuromuscular disease, muscle disease
Mental disorders
Immune disorder
malformation syndrome other than Down syndrome
Abnormal separate quantitative renal function (more than 20% left-right difference)
In this study, which the ratios of urine inulin excretion and intravenous inulin administration were <0.5 or >1.5
In this study, glomerular filtration rate >150 ml/min/1.73m2

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Tomohiko
Middle name
Last name Nishino

Organization

Saitama Children's Medical Center

Division name

Division of Nephrology

Zip code

330-8777

Address

1-2 Shintoshin, Chuo-ku, Saitama City, Saitama Prefecture 330 8777, Japan

TEL

048-601-2200

Email

sinonosino@yahoo.co.jp


Public contact

Name of contact person

1st name Tomohiko
Middle name
Last name Nishino

Organization

Saitama Children's Medical Center

Division name

Division of Nephrology

Zip code

330-8777

Address

1-2 Shintoshin, Chuo-ku, Saitama City, Saitama Prefecture 330 8777, Japan

TEL

048-601-2200

Homepage URL

http://www.pref.saitama.lg.jp/scm-c/rinsho/kenkyukadai_2018_05.html

Email

sinonosino@yahoo.co.jp


Sponsor or person

Institute

Division of Nephrology, Saitama Children's Medical Center

Institute

Department

Personal name



Funding Source

Organization

Self funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Saitama Children's Medical Center

Address

1-2 Shintoshin, Chuo-ku, Saitama City, Saitama Prefecture 330 8777, Japan

Tel

048-601-2200

Email

chiken@scmc.pref.saitama.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

埼玉県立小児医療センター(埼玉県)


Other administrative information

Date of disclosure of the study information

2019 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

0

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2019 Year 10 Month 29 Day

Date of IRB

2019 Year 01 Month 10 Day

Anticipated trial start date

2019 Year 12 Month 01 Day

Last follow-up date

2020 Year 03 Month 31 Day

Date of closure to data entry

2020 Year 03 Month 31 Day

Date trial data considered complete

2020 Year 03 Month 31 Day

Date analysis concluded

2020 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2019 Year 11 Month 25 Day

Last modified on

2020 Year 05 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044079


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name